Advertisement
A vs BIO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Bio-Rad Laboratories (BIO) Stock Comparison
Key Takeaways
- Agilent Technologies (A) reported stronger year-over-year revenue growth in its most recent quarter compared to Bio-Rad Laboratories (BIO), which posted modest reported growth but a currency-neutral decline.
- Analyst consensus rates (A) as Buy with higher average price targets relative to recent levels, while (BIO) holds a consensus of Hold.
- (A) operates with broader exposure to life sciences instruments and diagnostics, while (BIO) focuses on research tools and clinical diagnostics products with noted softness in academic markets.
- Recent market activity shows (A) with relatively stable positioning ahead of its upcoming quarterly results, whereas (BIO) adjusted its full-year outlook downward following its earnings release.
- Sector sentiment for both remains tied to life sciences spending trends, with (A) demonstrating more resilient order growth in certain segments during recent weeks.
- Relative performance metrics highlight trade-offs in growth consistency versus valuation multiples between the two healthcare names.
Introduction
This comparison examines Agilent Technologies (A) and Bio-Rad Laboratories (BIO), two established players in the life sciences and diagnostics sector. The analysis focuses on observable factors such as recent financial results, stock price behavior, analyst sentiment, and business positioning to provide traders and investors with a clear view of their relative characteristics. Institutional and individual market participants evaluating healthcare exposure, sector rotation opportunities, or stock-specific momentum may find this side-by-side review useful for understanding distinctions in performance drivers and risk profiles within the current market environment.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) develops and manufactures analytical instruments, software, and services primarily for life sciences, diagnostics, and applied chemical markets. In recent market activity, the stock has traded in a range influenced by broader sector dynamics and company-specific order trends. The firm reported first-quarter fiscal 2026 revenue of $1.80 billion, reflecting 7.0% reported growth and 4.4% core growth year-over-year. Order momentum showed improvement, including notable expansion in the clinical business. Analyst coverage maintains a Buy consensus with price targets clustered around $163. The company is scheduled to release second-quarter results on May 27, 2026, which could provide additional visibility into demand trends across its diversified customer base.
Bio-Rad Laboratories (BIO) Overview and Recent Performance
Bio-Rad Laboratories (BIO) supplies products for life science research and clinical diagnostics, including instruments, reagents, and software used in academic, pharmaceutical, and hospital settings. Recent performance reflects mixed results amid external pressures. First-quarter 2026 net sales reached $592.1 million, up 1.1% reported but down 4.2% on a currency-neutral basis, with softness in both Life Science and Clinical Diagnostics segments. The company recorded a GAAP net loss primarily due to investment valuation changes, though non-GAAP metrics remained positive. Management lowered its 2026 outlook for revenue and operating margins. Analyst ratings center on Hold, with targets near $303. Stock price movements in recent weeks have been shaped by these updates and ongoing monitoring of academic and geopolitical factors affecting end-market demand.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from its extensive library of hundreds of bots that trade thousands of different tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this section, based on factors such as consistency, risk-adjusted returns, and adaptability across varying timeframes and strategies. Available bots exhibit diverse performance statistics, with many reporting win rates in the 60-75% range and varying Sharpe ratios depending on their specific approach. Traders can explore these options to identify bots suited to individual risk preferences and market views. Trending AI Robots
Head-to-Head Comparison
Agilent Technologies (A) and Bio-Rad Laboratories (BIO) both operate within the healthcare equipment and supplies space but differ in business emphasis. (A) derives strength from a wider array of precision instruments and recurring service revenue, supporting more consistent growth in recent quarters. (BIO) maintains a concentrated portfolio in research and diagnostics consumables, which has faced greater pressure from academic budget constraints and regional disruptions. Momentum indicators favor (A) on order trends and analyst sentiment, while (BIO) offers potentially lower valuation multiples amid its recent outlook revision. Sector exposure remains similar, yet (A) appears positioned with greater resilience in biopharmaceutical and clinical end markets. Risk factors for both include macroeconomic sensitivity in research spending, though (BIO) carries additional exposure to fair-value adjustments on equity investments. Market sentiment has reflected these contrasts through divergent reactions to earnings updates in recent weeks.
Tickeron AI Verdict
Based on observable factors including stronger recent revenue growth, favorable analyst positioning, and upcoming earnings visibility, Tickeron’s AI models currently assign a higher probabilistic preference to Agilent Technologies (A) over Bio-Rad Laboratories (BIO). This assessment weighs trend consistency and catalyst potential without implying certainty, as market conditions and company execution can shift rapidly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and BIO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileBIO’s FA Score has 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- BIO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while BIO’s TA Score has 3 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 5 bearish.
- BIO’s TA Score: 3 bullish, 7 bearish.
Price Growth
A (@Medical Specialties) experienced а -3.14% price change this week, while BIO (@Medical/Nursing Services) price change was -2.82% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.45%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was -3.19%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.30%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
BIO is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical Specialties (+0.45% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-0.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| A | BIO | A / BIO | |
| Capitalization | 35.7B | 7.64B | 467% |
| EBITDA | 1.96B | 440M | 446% |
| Gain YTD | -6.662 | -7.221 | 92% |
| P/E Ratio | 25.40 | 46.77 | 54% |
| Revenue | 7.23B | 2.59B | 279% |
| Total Cash | 1.81B | 1.57B | 115% |
| Total Debt | 3.36B | 1.38B | 243% |
A | BIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 91 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 44 | 90 | |
PRICE GROWTH RATING 1..100 | 47 | 52 | |
P/E GROWTH RATING 1..100 | 62 | 13 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is significantly better than the same rating for BIO (83) in the Medical Specialties industry. This means that A’s stock grew significantly faster than BIO’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIO (100) in the Medical Specialties industry. This means that A’s stock grew similarly to BIO’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for BIO (90) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than BIO’s over the last 12 months.
A's Price Growth Rating (47) in the Biotechnology industry is in the same range as BIO (52) in the Medical Specialties industry. This means that A’s stock grew similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (13) in the Medical Specialties industry is somewhat better than the same rating for A (62) in the Biotechnology industry. This means that BIO’s stock grew somewhat faster than A’s over the last 12 months.
| A | BIO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 70% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 69% |
| MACD ODDS (%) | 2 days ago 59% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 67% |
| Advances ODDS (%) | 9 days ago 60% | 8 days ago 66% |
| Declines ODDS (%) | 7 days ago 62% | 2 days ago 68% |
| BollingerBands ODDS (%) | 2 days ago 52% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 75% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.